AU2001245209A1 - Screening methods for bone morphogenetic mimetics - Google Patents

Screening methods for bone morphogenetic mimetics

Info

Publication number
AU2001245209A1
AU2001245209A1 AU2001245209A AU4520901A AU2001245209A1 AU 2001245209 A1 AU2001245209 A1 AU 2001245209A1 AU 2001245209 A AU2001245209 A AU 2001245209A AU 4520901 A AU4520901 A AU 4520901A AU 2001245209 A1 AU2001245209 A1 AU 2001245209A1
Authority
AU
Australia
Prior art keywords
bone morphogenetic
methods
agents
mimetics
screening methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001245209A
Inventor
Dattatreymurty Bosukonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thrasos Inc
Original Assignee
Thrasos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thrasos Inc filed Critical Thrasos Inc
Publication of AU2001245209A1 publication Critical patent/AU2001245209A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Abstract

Disclosed are methods for identifying agents which modulate the activity of bone morphogenetic protein-7. These methods for identifying agents utilize bone morphogenetic protein receptors, specifically the daf-4 receptor, and more specifically the extracellular domain of the daf-4 receptor. Agents identified by the methods are also described as well as compositions comprising the agents and methods of treating a subject using the agents or compositions.
AU2001245209A 2000-11-06 2000-12-07 Screening methods for bone morphogenetic mimetics Abandoned AU2001245209A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24623100P 2000-11-06 2000-11-06
US60/246,231 2000-11-06
PCT/US2000/042657 WO2002039118A1 (en) 2000-11-06 2000-12-07 Screening methods for bone morphogenetic mimetics

Publications (1)

Publication Number Publication Date
AU2001245209A1 true AU2001245209A1 (en) 2002-05-21

Family

ID=22929832

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001245209A Abandoned AU2001245209A1 (en) 2000-11-06 2000-12-07 Screening methods for bone morphogenetic mimetics

Country Status (8)

Country Link
US (3) US20040009532A1 (en)
EP (1) EP1334365B1 (en)
AT (1) ATE354802T1 (en)
AU (1) AU2001245209A1 (en)
CA (1) CA2431552A1 (en)
DE (1) DE60033576T2 (en)
ES (1) ES2282163T3 (en)
WO (1) WO2002039118A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000501744A (en) * 1996-01-22 2000-02-15 クリエイティブ バイオモレキゥルズ，インコーポレーテッド Morphogen analogs and their preparation
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US7371719B2 (en) 2002-02-15 2008-05-13 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
JP4654029B2 (en) * 2002-06-17 2011-03-16 トラソス インコーポレイテッド Single domain TDF related compounds and analogs thereof
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
DK1677735T3 (en) 2003-10-17 2014-10-27 Joslin Diabetes Center Inc METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION
JP4851939B2 (en) 2003-12-05 2012-01-11 ノースウエスタン ユニバーシティ Self-assembling peptide amphiphiles and related methods for growth factor delivery
JP4971149B2 (en) 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド TDF related compounds and analogs thereof
EP1847265A4 (en) * 2005-01-26 2008-04-30 Mian Long The use of flavonol and flavonol glycosides for stimulating growth of renal tubular epithelial cells to secrete the kidney secreting bone growth factor
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
DK2497780T3 (en) 2005-09-20 2015-06-01 Thrasos Innovation Inc TDF-related compounds and analogs thereof
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
CA2700831A1 (en) * 2007-09-28 2009-04-09 Stryker Corporation Methods for detecting neutralizing antibodies for bone morphogenetic proteins
CA2758522A1 (en) 2009-04-13 2010-10-21 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5650276A (en) * 1991-03-11 1997-07-22 Creative Biomolecules, Inc. Morphogenic protein screening method
US6071695A (en) * 1992-02-21 2000-06-06 Creative Biomolecules, Inc. Methods and products for identification of modulators of osteogenic protein-1 gene expression
US6248554B1 (en) * 1993-11-24 2001-06-19 The Procter & Gamble Company DNA sequence coding for a BMP receptor
JPH10511840A (en) * 1994-04-29 1998-11-17 クリエイティブ バイオモレキュールズ，インコーポレイテッド Morphogenetic protein-specific cell surface receptors and uses thereof
AU2404695A (en) * 1994-05-04 1995-11-29 Mount Sinai Hospital Corporation Modulators of cytokines of the tgf-beta superfamily and methods for assaying for same
US6083690A (en) * 1995-06-02 2000-07-04 Osteoscreen, Inc. Methods and compositions for identifying osteogenic agents
US6190659B1 (en) * 1996-09-17 2001-02-20 The Rockefeller University Bacterial plasmin binding protein and methods of use thereof
WO2000061774A2 (en) * 1999-04-09 2000-10-19 Human Genome Sciences, Inc. Bone morphogenic proteins

Also Published As

Publication number Publication date
ATE354802T1 (en) 2007-03-15
US20040009532A1 (en) 2004-01-15
WO2002039118A1 (en) 2002-05-16
ES2282163T3 (en) 2007-10-16
EP1334365B1 (en) 2007-02-21
US20110081662A1 (en) 2011-04-07
CA2431552A1 (en) 2002-05-16
EP1334365A1 (en) 2003-08-13
US20090124537A1 (en) 2009-05-14
DE60033576D1 (en) 2007-04-05
WO2002039118A8 (en) 2002-12-27
DE60033576T2 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
AUPO755097A0 (en) Receptor agonist and antagonist
AU4968397A (en) Antipruritic
TR200100267T2 (en) Substituted anilide compositions and methods.
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics
TW200607814A (en) Cell surface receptor isoforms and methods of identifying and using the same
WO2000006085A3 (en) Compounds and methods
AU4926301A (en) Lpa receptor agonists and antagonists and methods of use
EP1073465A4 (en) T cell inhibitory receptor compositions and uses thereof
MXPA04006280A (en) Spiroazacyclic compounds as monoamine receptor modulators.
WO2003002717A3 (en) Biological activity of ak155
AR038563A1 (en) ZIPRASIDONE COMPOSITION AND SYNTHETIC CONTROLS
ES2168650T3 (en) COMPOUNDS AND MODULATING METHODS OF ANDROGEN RECEPTORS.
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
YU80902A (en) Indolin-2-one derivateves, preparation and their use as ocytocin receptor ligands
ATE273956T1 (en) ARYL-SUBSTITUTED OLEFINIC AMINE AND THEIR USE AS CHOLINERGIC RECEPTOR AGONISTS
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
HK1051324A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity.
AP9801269A0 (en) Prostaglandin agonists.
EA199800867A1 (en) COMPOUNDS TETRAHYDROBETAKARBOLINA
MY133390A (en) Azabicyclic 5ht1 receptor ligands
DK0900218T3 (en) Heterocyclic compounds
WO2004067725A3 (en) Methods of identifying modulators of nmur2-mediated activity
GB0213698D0 (en) Receptor
AU2002251873A1 (en) Methods and compositions for modulating gluconeogenesis using pgc-1